Phlexglobal

About 

Inflexion supported planned succession and international growth of TMF services provider Phlexglobal to generate 2.8x money.   

Phlexglobal is a specialist provider of tech-enabled document management solutions to the global clinical research market. The business employs around 200 people in the UK and US, and counts a significant majority of the top 20 global pharmaceutical companies among its clients. In 2014 the firm was sold to Bridgepoint Development Capital, generating a 2.8x return on investment.  

Value acceleration 

Inflexion’s investment allowed the founder to transition out of the business and provided an opportunity to strengthen the management team. The business rapidly expanded international operations, opening a new office in Pennsylvania in the US to target North American pharma clients, and assessing the opportunity in India and Asia Pacific through Inflexion’s international experts. Phlexglobal also accelerated investment in its core technology platform and its service provision.